News › Clinical Practice, Industry News, Patient Care

FDA approves HA filler for midface via cannula injection

November 30, 2018

Galderma Laboratories announced in November 2018 that the FDA approved its hyaluronic acid dermal filler Restylane Lyft for correction of age-related midface deformities and cheek augmentation via a small blunt tip cannula.
One of the biggest debates in aesthetic medicine today is whether dermal fillers are best injected using cannulas or needles, according to Manhattan-based dermatologist Anne Chapas, M.D. Dr. Chapas was an investigator for the Galderma midface cannula study, which led to the FDA’s most recent approval for Restylane Lyft.
Read more at The Aesthetic Channel >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics Refreshes Allergan Partner Privileges to Better Support Today’s Modern Aesthetics Practices
    • Galderma Receives EU Approval for Restylane Shaype: Bone-Mimicking Hyaluronic Acid Injectable for Chin
    • Merz Aesthetics’ Ultherapy PRIME Gains FDA Clearance for Knee Skin Laxity
    • USA Payments Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Accepts Supplemental Biologics License Application for Botox Cosmetic for Masseter Muscle Prominence
Advertisement